• 女性之声——全国妇联 2019-06-23
  • 人民网旅游3·15投诉平台--旅游频道 2019-06-20
  • 2018中国双一流大学专业排行榜发布 清华大学位列第一 2019-06-20
  • 今天,首艘国产航母下水!这六大方面信息你得掌握 2019-06-16
  • 央行金融市场流动性合理稳定 经济金融运行平稳 2019-06-14
  • 【理上网来·辉煌十九大】 2019-05-11
  • 中华龙舟如何奋楫争先?习近平这些话要牢记 2019-04-12
  • 楼市调控重点转向三四线城市 释放什么信号? 2019-04-12
  • 国家行政学院中国领导科学研究中心副秘书长雷强做客人民网 2019-04-11
  • 新华时评:不忘初心 向善前行 2019-04-05
  • 对话国家体育总局副局长高志丹 2019-03-30
  • 岚山区:婚育新风吹进基层 2019-03-30
  • 停止接客!杭州奥体某盘摇号在即 购房者头顶烈日前往 ——凤凰网房产 2019-03-29
  • 四川破获一起盗用“老板”微信骗财务转账案 2019-03-29
  • 七一党课:严书翰教授谈重温“不忘初心” 2019-03-26
  • 第一金融网主办
    »您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

    Takeda Completes Sale of Xiidra to Novartis

    2019/7/3 10:19:25  文章来源:文传商讯  作者:文传商讯
    文章简介: OSAKA,Japan--(BUSINESSWIRE)-- TakedaPharmaceuticalCompanyLimited(TSE:4502/NYSE:TAK)(“Takeda”)todayannouncedthecompletionofi

    电子游戏 www.hpqjf.com OSAKA, Japan -- (BUSINESS WIRE) --

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.

    “The completion of this transaction marks an important step in executing Takeda’s strategy, which is focused on optimizing our portfolio around the key business areas that are core to our long-term growth and creating the most value for our patients and shareholders,” said Christophe Weber, President and Chief Executive Officer of Takeda. “We are making solid progress on our commitment to simplify our portfolio and meet our deleveraging targets, while continuing to deliver highly-innovative medicines and transformative care to patients around the world and enhance long-term shareholder value. We are proud of the benefits Xiidra® has created for patients as part of Takeda, and confident that Novartis will be a strong steward of this innovative therapeutic.”

    Takeda intends to use the proceeds from the sale to reduce its debt and accelerate deleveraging toward its target of 2x net debt/adjusted EBITDA in the medium term following closing of the Shire acquisition. As of March 31, 2019, Takeda has 5,048.9 billion yen in net debt outstanding and its net debt/adjusted EBITDA ratio is 4.7x. Takeda continues to target a net debt/adjusted EBITDA ratio of 2x within 3 to 5 years.

    Xiidra® is the first and only prescription treatment approved by the U.S. Food and Drug Administration for both signs and symptoms of dry eye disease, with a mechanism of action that targets inflammation.

    About Takeda Pharmaceutical Company Limited

    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

    For more information, visit https://www.takeda.com

    Forward-Looking Statements

    This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward looking statements often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. Any forward-looking statements in this document are based on the current assumptions and beliefs of Takeda in light of the information currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products or products candidates; and post-merger integration with acquired companies, any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations. Persons receiving this press release should not place undue reliance on forward looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20190701005660/en/

    CONTACT:

    Investor Relations:
    Takashi Okubo
    +81-(0)3-3278-2306
    [email protected]

    Media Inquiries:
    Julia Ellwanger (Outside of Japan)
    +1-224-554-7681
    [email protected]

    Kazumi Kobayashi (Japan)
    +81 (0)3-3278-2095
    [email protected]

    分享到:
    第一金融网免责声明:
    1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
    2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
    3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
    发表评论

    【发表评论】(网友评论内容只代表网友观点,与本站立场无关?。?/td>
     姓 名:
     评 分: 1分 2分 3分 4分 5分
     评论内容:
    验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  葛洲坝电力被拉黑背后:高层调整,有项目分包商
     中国“神船”来了 南船北船拟重组将成市值最高造
    [银行]  招行交行浦发齐发声:未受到相关制裁调查
     央行:55万户中小微企业获信贷支持,贷款余额11
    [股票]  提速!证监会一天同意7家公司科创板IPO注册 一文
     官宣了!两大造船集团拟重组"中国神船"即将出世
    [基金]  大盘重回3000点 大涨底气在哪?基金最新解读来了
     A股酝酿变盘信号!公募逆势加仓,北上资金调仓换
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  大跌4%!油价快到50美元 这是个让美国尴尬的位置
     国际油价连续破位下跌 原油类QDII净值“很受伤”
    [股评]  券商评级:三大股指全线收阳 九股迎掘金良机
     波司登第三次“回怼”做空机构报告 股价继续反弹
    [港股]  二次上市回到香港 阿里和港交所将得到什么?
     小米"成长的烦恼":股价几近腰斩 主营亟待破局
    [美股]  苹果召回部分MacBook Pro笔记本电脑 存在“火灾
     2019京东618销售成绩单出炉
    [外汇]  贸易战犹如高悬在人民币头顶的达摩克利斯之剑 落
     央行喊话!潘功胜霸气强调"完全有能力保持汇市稳
    [债券]  中国债市:隔夜回购创近十年新低
     施罗德投资:6月全球债市进入避险模式
    [黄金]  刘智辛:欧美货币持稳,黄金日线三连阳,原油多
     央行连续4个月耗资120亿元爆买黄金!全球都在买
    [理财]  郭美美将刑满释放 回想她炫富的样子 仿佛就在昨
     炎夏养生须谨记:一觉、二瓜、三汤、四穴、五果
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  251次破纪录: 三维解读上半年楼市调控政策
     二三线城市争建摩天大楼 天际线下暗藏风险
    [汽车]  北京市实施“国六”机动车排放标准首日见闻
     7月重磅新规实施!2019车辆购置税按裸车价交税
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 电子游戏 All Rights Reserved 版权所有·电子游戏 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以电子游戏名义做股票推荐的行为均属违法!

    广告商的言论与行为均与电子游戏无关!股市有风险,投资需谨慎。

    合作邮箱:电子游戏 合作电话:18678839953 点击这里给我发消息

  • 女性之声——全国妇联 2019-06-23
  • 人民网旅游3·15投诉平台--旅游频道 2019-06-20
  • 2018中国双一流大学专业排行榜发布 清华大学位列第一 2019-06-20
  • 今天,首艘国产航母下水!这六大方面信息你得掌握 2019-06-16
  • 央行金融市场流动性合理稳定 经济金融运行平稳 2019-06-14
  • 【理上网来·辉煌十九大】 2019-05-11
  • 中华龙舟如何奋楫争先?习近平这些话要牢记 2019-04-12
  • 楼市调控重点转向三四线城市 释放什么信号? 2019-04-12
  • 国家行政学院中国领导科学研究中心副秘书长雷强做客人民网 2019-04-11
  • 新华时评:不忘初心 向善前行 2019-04-05
  • 对话国家体育总局副局长高志丹 2019-03-30
  • 岚山区:婚育新风吹进基层 2019-03-30
  • 停止接客!杭州奥体某盘摇号在即 购房者头顶烈日前往 ——凤凰网房产 2019-03-29
  • 四川破获一起盗用“老板”微信骗财务转账案 2019-03-29
  • 七一党课:严书翰教授谈重温“不忘初心” 2019-03-26
  • 河北十一选五码型走势图 风暴魔域幻兽进化三阶 明日之后新版bug大全 泛珠体彩36选7走势图 龙族幻想壁纸 巨人财富是什么意思 巴塞罗那球票退票 13年福彩3d走势图 冰球刀如何磨刀 香港赛马会一肖中特 以太币价格行情 山东群英会玩法表 万博ag真人会作假吗 20选5尾数走势图 2014年七星彩走势图 英雄联盟之灾变时代